PU02.01 | Subtle variations in HIV-1 subtype C env sequence features obtained from a slow progressing Indian donor and their association with sensitivity to neutralizing antibodies with distinct epitope specificities | Publication Only | Broadly neutralizing antibodies |
PU01.09 | Supporting adolescent girls and young women to adhere to oral PrEP; experiences of counsellors at the Kampala site | Publication Only | Behavioural and social science research |
PE26.01 | Surge strategies improve HIV testing efficiency and linkage to treatment among female sex workers in Nairobi, Kenya | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
OA11.03 | Surveillance data from public and private primary care facilities uncover implementation successes and gaps during pre-exposure prophylaxis (PrEP) scale-up: results from the Jilinde project in Kenya | Oral Abstract Session | Implementation science, including structural interventions, PrEP & VMMC |
PE11.02 | Switching from F/TDF to F/TAF for HIV Pre-exposure Prophylaxis: An Analysis of the Real-World Data | E-poster | Discovery and evaluation of biomedical agents |
PE01.08 | Syndemic conditions and PrEP use are independently associated with rectal inflammation in sexual minority men | E-poster | Behavioural and social science research |
PE16.14 | Targeted index partner HIV self-testing results in high positivity yield and reach for exposed HIV-uninfected contacts at elevated ongoing risk of HIV acquisition in Kenya | E-poster | Implementation science, including structural interventions, PrEP & VMMC |
OA14.04 | Targeting Sphingosine-1-phosphate signaling prevents cell-to-cell transmission of HIV-1 | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
OA22.03 | Temporal and spatial characterization of SIV infection dynamics in rhesus macaque mucosal tissues | Oral Abstract Session | Mucosal immunity |
PE23.03 | Ten years of the AVAC Advocacy Fellows Program: An evaluation | E-poster | Policy and advocacy |